Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 25;8(2):3072–3103. doi: 10.18632/oncotarget.13618

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2017 De et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

A. Oncoprints (cBioPortal) showing alterations in RAC1 gene in Breast Invasive Carcinoma (TCGA Nature 2012) and subtypes including PAM50 Luminal A, PAM50 Luminal B, PAM50 HER2 and PAM50 Basal. The patient selected were, (1) Breast Invasive Carcinoma; (825 patients/825 samples), (2) Breast Invasive Carcinoma, PAM50 Luminal A (235 patients/235 samples), (3) Breast Invasive Carcinoma, PAM50 Luminal B (133 patients/133 samples), (4) Breast Invasive Carcinoma, PAM50 HER2 (58 patients/58 samples) and (5) Breast Invasive Carcinoma, PAM50 Basal (81 patients/81 samples). B. Oncoprints (cBioPortal) showing alterations in RAC1 gene in ER+ve (upper panel) and ER-ve (lower panel) Breast Invasive Carcinoma (TCGA Cell 2015) brca/tcga/pub2015. The oncoprints are generated using 594 patients/594 samples for ER+ve and 174 patients/174 samples for ER-ve breast tumors. C. Oncoprints (cBioPortal) showing alterations in RAC1 gene in Breast Invasive Carcinoma (TCGA Cell 2015) and subtypes including PAM50 Luminal A, PAM50 Luminal B, PAM50 HER2 and PAM50 Basal. The patient selected were, (1) Breast Invasive Carcinoma; (1105 patients/1105 samples), (2) Breast Invasive Carcinoma, PAM50 Luminal A (201 patients/201 samples), (3) Breast Invasive Carcinoma, PAM50 Luminal B (112 patients/112 samples), (4) Breast Invasive Carcinoma, PAM50 HER2 (51 patients/51 samples) and (5) Breast Invasive Carcinoma, PAM50 Basal (107 patients/107 samples). Advanced cancer genomic data visualization is obtained with the help of “The Onco Query Language (OQL)”. Oncoprints (different levels of zoom) have been generated using cBioPortal. Individual genes are represented as rows, and individual cases or patients are represented as columns. Protein level obtained from IHC staining (cBioPortal).